These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

734 related articles for article (PubMed ID: 8177717)

  • 41. [Evaluation of viral safety of a high-purity human factor VIII concentrate submitted to 2 specific virus inactivation treatments (FANDHI)].
    Ristol P; Gensana M; Fernández J; Massot M; Biescas H; Darling A; Jorquera JI; Vericat F
    Sangre (Barc); 1996 Apr; 41(2):131-6. PubMed ID: 9045353
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Plasma derivatives: new products and new approaches.
    Sauna ZE; Pandey GS; Jain N; Mahmood I; Kimchi-Sarfaty C; Golding B
    Biologicals; 2012 May; 40(3):191-5. PubMed ID: 22239993
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Immunologic studies in asymptomatic hemophiliac patients.
    Frydecka I; Kowalewska B; Lesiecki A; Kuliczkowski K; Palakowska A; Polkowski A
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1986; 113(5):708-15. PubMed ID: 2435638
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Hepatitis C and pasteurised factor VIII and IX concentrates.
    Klarmann D; Kreuz W; Auerswald G; Auberger K; Rabenau H; Gürtler L; Roggendorf M
    Thromb Haemost; 1995 Apr; 73(4):736-7. PubMed ID: 7495095
    [No Abstract]   [Full Text] [Related]  

  • 45. [A factor IX-concentrate for the treatment of haemophilia B].
    Suomela H; Myllylä G
    Duodecim; 1971; 87(1):31-8. PubMed ID: 5539580
    [No Abstract]   [Full Text] [Related]  

  • 46. The management of hemophilia patients with inhibitors.
    Nilsson IM
    Transfus Med Rev; 1992 Oct; 6(4):285-93. PubMed ID: 1421831
    [No Abstract]   [Full Text] [Related]  

  • 47. [Substitution therapy of hemorrhagic diseases].
    Haupt H
    Anasthesiol Intensivmed Prax; 1975 Oct; 11(1):137-44. PubMed ID: 1225069
    [No Abstract]   [Full Text] [Related]  

  • 48. Therapeutic properties and safety of recombinant factor VIII and factor IX.
    Zdziarska J; Chojnowski K; Klukowska A; Łetowska M; Mital A; Podolak-Dawidziak M; Windyga J; Zawilska K;
    Pol Arch Med Wewn; 2009 Jun; 119(6):403-9. PubMed ID: 19694223
    [TBL] [Abstract][Full Text] [Related]  

  • 49. In vivo recovery of factor VIII and factor IX: intra- and interindividual variance in a clinical setting.
    Björkman S; Folkesson A; Berntorp E
    Haemophilia; 2007 Jan; 13(1):2-8. PubMed ID: 17212717
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Treatment of patients with hemophilia A having antibodies to factor VIII].
    Lopaciuk S; Ziemski JM
    Acta Haematol Pol; 1979; 10(2):115-22. PubMed ID: 474044
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Substitution treatment in hemophilia. Critical measures and complications].
    Schimpf K
    Wien Med Wochenschr; 1977 Jun; 127(11):329-37. PubMed ID: 878496
    [No Abstract]   [Full Text] [Related]  

  • 52. Inhibitors in young boys with haemophilia.
    Lusher JM
    Baillieres Best Pract Res Clin Haematol; 2000 Sep; 13(3):457-68. PubMed ID: 11030045
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Virus safety of pasteurized factor VIII and factor IX concentrates: study in virgin patients.
    Heimburger N; Karges HE; Weidmann E
    Dev Biol Stand; 1987; 67():303-10. PubMed ID: 3038638
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Hemophilia and prophylaxis.
    Ljung R
    Pediatr Blood Cancer; 2013; 60 Suppl 1():S23-6. PubMed ID: 23109472
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Clinical and biological survey of haemophilia A and B patients infused with French heat-treated concentrates.
    Parquet A; Boneu B; Bosser C; Cazenave JP; Dirat G; Gazengel G; Grunebaum L; Sultan Y; Verroust F; Wiesel ML
    Nouv Rev Fr Hematol (1978); 1988; 30(4):205-7. PubMed ID: 3143099
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Production of antihemophilic factor in France.
    Allain JP
    Scand J Haematol Suppl; 1984; 40():499-503. PubMed ID: 6433471
    [No Abstract]   [Full Text] [Related]  

  • 57. A therapeutic concentrate of coagulation factors II, IX and X from citrated, factor VIII-depleted plasma.
    Middleton SM; Bennett IH; Smith JK
    Vox Sang; 1973 May; 24(5):441-56. PubMed ID: 4691239
    [No Abstract]   [Full Text] [Related]  

  • 58. The evolution of recombinant factor replacement for hemophilia.
    Sankar AD; Weyand AC; Pipe SW
    Transfus Apher Sci; 2019 Oct; 58(5):596-600. PubMed ID: 31421983
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Technic of obtaining the antihemophilic factors VIII and IX and their clinical application].
    Triginer J; Vila M; Vicente Arangüena P
    Sangre (Barc); 1979; 24(5-C):937-41. PubMed ID: 121169
    [No Abstract]   [Full Text] [Related]  

  • 60. Specific therapy in hemophilia.
    Hutaff LW
    N C Med J; 1973 Mar; 34(3):193-6. PubMed ID: 4510809
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 37.